However, there were more HR+/HER2- breast cancers in BRCA2 mutation-carriers (57.0%) and fewer in BRCA1 mutation-carriers (22.6%) than the non-carriers (40.9%, p=1.4×10-5 and 3.0×10-4, respectively). Here, ERBB2 is linked to breast carcinoma.